Table 2. Vaccine characteristics and results.
| Patient ID | Vaccine route | Quality of DC %CD83/%CD86/ %HLA-DR | Number of vaccinations | DTH | Immune response | Log PSA slopea | Clinical outcome |
|---|---|---|---|---|---|---|---|
| P01 | i.n. | 27.8/98.7/95.2 | 4 | − | − | − | PDb |
| P02 | i.n. | 25.7/92.6/81.7 | 4 | NT | − | + | SDb |
| P03 | i.n. | 34.0/95.8/89.3 | 4 | − | + | + | SD |
| P04 | i.n. | 13.1/96.1/88.3 | 4 | − | − | + | PDb |
| P05 | i.n. | 44.7/97.7/91.9 | 4 | + | + | + | SDb |
| P06 | i.n. | 11.1/94.3/93.6 | 4 | + | − | + | PDb |
| P07 | i.n. | 91.4/94.4/96.1 | 4 | NT | − | − | PDb |
| P08 | i.n. | 91.0/99.7/99.8 | 5 | + | + | + | SDb |
| P09 | i.n. | 97.0/99.7/98.6 | 4 | NT | − | − | PDb |
| P10 | i.d. | 94.6/99.5/97.8 | 5 | + | + | − | PDb |
| P11 | i.d. | 72.7/92.5/88.1 | 4 | − | + | − | SDb |
| P12 | i.d. | 92.0/99.0/96.3 | 4 | − | + | + | SDb |
| P13 | i.d. | 86.0/97.0/89.7 | 4 | − | + | + | SD |
| P14 | i.d. | 90.5/99.0/96.6 | 4 | + | + | + | PDb |
| P15 | i.d. | 95.7/98.8/99.3 | 4 | − | + | + | SDb |
| P16 | i.d. | 94.8/98.8/98.4 | 6 | − | + | + | SD |
| P17 | i.d. | 84.8/99.6/97.3 | 5 | − | + | + | SD |
| P19 | i.n. | 90.6/99.4/97.0 | 6 | − | + | + | SDb |
| P20 | i.d. | 96.1/98.5/97.2 | 4 | − | − | − | PD |
DC=dendritic cells; DTH=delayed-type hypersensitivity; PSA=prostate-specific antigen; i.n.=intranodal; i.d.=intradermal; NT=not tested; SD=stable disease; PD=progressive disease.
a
Decrease in slope marked as ‘+’.
b
Indicate the patient is positive in bone scan.